1.Clinical analysis on the treatment of hysteroscopic resection and norethisterone in abnormal uterine bleeding
Yanqin JI ; Fengying WANG ; Xiuzhen OUYANG
Chinese Journal of Primary Medicine and Pharmacy 2006;0(12):-
Objective To analyse the efficacy of hysteroscopic resection and norethisterone in abnormal uterine bleeding.Methods 38 cases of submucos myoma of uterine body,26 cases of endometrium polyps and 16 cases of complex hyperplasis of endometrium were treated with hysteroscopic resection,and all the cases take norethisterone for one month before hysteroscopic resection and go on taking norethisterone for three months after operation.All the cases were followed up with the improvement of symptoms and the chang of uterine cavity.Results All the cases were followed up for 3~18 months after operation.The efficacy of submucous myoma of uterine body was 92.10%(36/38) and that of endometrium polyps was 84.61%(22/26) and that of complex hyperplasis of endometrium was 93.75%(15/16).Conclusion The treatment of hysteroscopic resection and norethisterone in submucous myoma,endometrium polyps and complex hyperplasis has advantages of satisfied results,slight trauma,fast recovery and fewer recurrence relapse.
2.Progress in synaptic mechanism in epileptogenesis
Xiuzhen XIAO ; Yuanhan OUYANG ; Zhi SONG ; Wen ZHENG
Journal of Central South University(Medical Sciences) 2018;43(1):90-94
Recurrent seizures lead to abnormal expression of synaptic proteins,reorganization of synapse and formation of abnormal neuron network.Recently,it is identified that the synaptic proteins are involved in epileptogenesis.The abnormal expression of several synaptic regulatory proteins and postsynaptic membrane receptor proteins may result in epilepsy.The ion channels usually are the action target of most antiepileptic drugs.However,carbamazepine and zonisamide may interact with syntaxin and/or soluble N-ethylmaleimide-sensitive factor attachment protein receptor complex to exert its function of anti-epilepsy.The synaptic vesicle protein 2A is the action target for new anti-epileptic drugs,including levetiracetam,brivaracetam and seletracetam.